Anti-Xa assays

Australian Prescriber

Volumn 36, Issue 3, 2013, Pages 98-101

  Barras, Michael ^a  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Anticoagulation; Low molecular weight heparins; Thromboembolism

Indexed keywords

BLOOD CLOTTING FACTOR 10A; DALTEPARIN; DANAPAROID; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ANTICOAGULATION; ARTICLE; AUSTRALIA; BLEEDING; BLOOD CLOTTING TIME; CALIBRATION; CONSENSUS DEVELOPMENT; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG ACTIVITY; DRUG BINDING; DRUG DETERMINATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MONITORING; HUMAN; HYDROPHILICITY; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LABORATORY TEST; MAXIMUM PLASMA CONCENTRATION; OBESITY; PARTIAL THROMBOPLASTIN TIME; PATIENT MONITORING; PREGNANCY; STEADY STATE; THERAPEUTIC EQUIVALENCE; TREATMENT CONTRAINDICATION;

EID: 84878491863     PISSN: 03128008     EISSN: None     Source Type: Journal    
DOI: 10.18773/austprescr.2013.036     Document Type: Article

References (14)

1. Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:141S-59S.
2. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuunemann HJ. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:7S-47S.
3. Barras MA, Kirkpatrick CM, Green B. Current dosing of low-molecular-weight heparins does not reflect licensed product labels: an international survey. Br J Clin Pharmacol 2010;69:520-8.
4. Favaloro EJ, Lippi G, Koutts J. Laboratory testing of anticoagulants: the present and the future. Pathology (Phila) 2011;43:682-92.
5. Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators. J Am Coll Cardiol 1997;29:1474-82.
6. Montalescot G, Collet JP, Tanguy ML, Ankri A, Payot L, Dumaine R, et al. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation 2004;110:392-8.
7. Al-Sallami HS, Barras MA, Green B, Duffull SB. Routine plasma anti-Xa monitoring is required for low-molecular-weight heparins. Clin Pharmacokinet 2010;49:567-71.
8. Nutescu EA, Spinler SA, Wittkowsky A, Dager WE. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother 2009;43:1064-83.
9. Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e691S-736S.
10. Lim W, Dentali F, Eikelboom JW, Crowther MA. Metaanalysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006;144:673-84.
11. DeCarolis DD, Thorson JG, Clairmont MA, Leuthner AM, Rector TS, Johnson GJ. Enoxaparin outcomes in patients with moderate renal impairment. Arch Intern Med 2012;172:1713-8.
12. Green B, Duffull SB. Development of a dosing strategy for enoxaparin in obese patients. Br J Clin Pharmacol 2003;56:96-103.
13. Barras MA, Duffull SB, Atherton JJ, Green B. Individualised compared to conventional dose of enoxaparin. Clin Pharmacol Ther 2008;83:882-8.
14. Gulati A, Faed JM, Isbister GK, Duffull SB. Development and evaluation of a prototype of a novel clotting time test to monitor enoxaparin. Pharm Res 2012;29:225-35.